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Reply to Drs. Angulo and Collignon
To the Editor: Drs. Angulo and Collignon point
out that exposure to one antimicrobial drug
(e.g., tetracycline) can confer a selective
advantage to a multiresistant organism (e.g., R-
type ACSSuT) over nonresistant organisms.
However, tetracycline use would not be
expected to favor one tetracycline-resistant
organism (MR-DT104) over other tetracycline-
resistant organisms, and most bovine
Typhimuriums before the MR-DT104 epidemic
were tetracycline-resistant R-type ASSuT.
Since neither florfenicol nor chloramphenicol
was then available for use in livestock in the
United States, the evidence suggests that the
emergence of MR-DT104 in cattle populations
was not driven by antibiotic selection pressure.
The references Drs. Angulo and Collignon cited
to establish the importance of antimicrobial use
in livestock for the dissemination of
multiresistant clones either do not address the
issue of dissemination (1-2) or present evidence
to the contrary: the dissemination of
fluoroquinolone-resistant MR-DT104 despite
the lack of fluoroquinolone use in the herds in
question (3).
Available data support Dr. Collignon’s
example of Campylobacter as an agent for
which fluoroquinolone use in livestock resulted
in increasing prevalence of fluoroquinolone
resistance (4). However, the epidemiology of
resistance in polyclonal commensals such as
Campylobacter is very unlike that of epidemic,
clonal S. Typhimuriums. The epidemic, clonal
dissemination of S. Typhimurium more closely
resembles that of methicillin-resistant Staphy-
lococcus aureus (MRSA). Epidemic MRSA
clones differ genetically from nonepidemic ones,
and dissemination of epidemic clones does not
necessarily require antimicrobial selection
pressure (5). Because antimicrobial usage
practices that contribute to the control of MRSA
have not been scientifically defined, infection
control practices must play the central role in
successful MRSA control programs (6-8).
Dr. Angulo’s hypothesis that MR-DT104
emerged genetically in Asian fish is plausible,
but other credible hypotheses exist. tet(G), first
described in Vibrio angullarium, also occurs in
Pseudomonas aeruginosa (9). Similarly, floR is
closely related to the P. aeruginosa
chloramphenicol-resistance gene cmlA (10), and
pse-1 encoded beta-lactamase is a common
feature of hospital P. aeruginosa isolates (11).
Thus, the hypothesis that MR-DT104 acquired
resistance genes horizontally from nosocomial
pseudomonads might also be worthy of
consideration.
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Salmonella infections acquired in other
countries are frequently diagnosed in travelers
recently returned to the United States. Al-
though transmission of these infections to other
humans may be rare in the United States,
human-to-bovine transmission may occur
regularly: thousands of cases of bovine Taenia
saginata cysticercosis occurred immediately
before and during the dissemination of MR-
DT104. As humans are the only definitive host
of the T. saginata tapeworm, these cases
confirm the large-scale occurrence of human-to-
animal transmission of enteropathogenic agents
in the United States. Since transmission of
S. Typhimurium from herd to herd is common
in the United States, increased emphasis on
Salmonella infection control may be an effective
method for reducing dissemination of organ-
isms such as MR-DT104.
With or without imposition of stringent
controls on antibiotic use in the United States
and Europe, the future genetic emergence of
new epidemic clones of S. Typhimurium some-
where in the world is highly likely, and control-
ling the dissemination of epidemic clones is
essential to avoid increasing problems with
multidrug resistance. Certainly we do not
disagree with the concept of reducing antimi-
crobial use, particularly such frivolous use as in
calf milk replacers. However, we urge public
health officials to consider that infection control
is as central to control of agents such as MR-
DT104 as it is for epidemic MRSA.
Margaret A. Davis, Dale D. Hancock,
Thomas E. Besser, Daniel H. Rice, John M. Gay
Washington State University, Pullman,
Washington, USA
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Malaria and Global Warming in
Perspective?
To the Editor: The two reports from the Inter-
national Panel on Climate Change (IPCC) (1,2)
cited in the letter by Pim Martens (3) are
widely regarded as “the standard scientific
reference for all concerned with climate change
and its consequences,” yet the contents of these
reports are often misleading. The quoted
passage does not acknowledge the devastation
caused by malaria in temperate regions. The
reassurance that “existing public health re-
sources” would “make reemergent malaria
unlikely” ignores the nonclimatic factors that
led to its disappearance and continued absence.
Moreover, although malaria/climate models are
not meant to predict future worlds, the IPCC
chapter (1) on human health—one-third of
which is devoted to vector-borne disease—
makes extensive use of such models to warn of
substantial “actual climate-related increases in
malaria incidence” and “highly likely” exten-
